



PTO/SB/08a (07-09)

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449/PTO</p> <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(Use as many sheets as necessary)</p>				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	1	of	57	Attorney Docket Number	C1271.70021US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1*	US-3,450,693	06-17-1969	Suzuki <i>et al.</i>	
	A2*	US-3,670,086	06-13-1972	Pryor <i>et al.</i>	
	A3*	US-3,692,907	09-19-1972	Fierning <i>et al.</i>	
	A4*	US-3,891,660	06-24-1975	Denzel <i>et al.</i>	
	A5*	US-3,899,508	08-12-1975	Wikel	
	A6*	US-3,917,624	11-04-1975	Abu El-Haj <i>et al.</i>	
	A7*	US-4,006,237	02-01-1977	Buckle <i>et al.</i>	
	A8*	US-4,053,588	10-11-1977	Konig <i>et al.</i>	
	A9*	US-4,381,344	04-26-1983	Rideout <i>et al.</i>	
	A10*	US-4,552,874	11-12-1985	Mardin <i>et al.</i>	
	A11*	US-4,563,525	01-07-1986	Campbell, Jr.	
	A12*	US-4,593,821	06-10-1986	Brule	
	A13*	US-4,668,686	05-26-1987	Meanwell <i>et al.</i>	
	A14*	US-4,690,930	09-01-1987	Takada <i>et al.</i>	
	A15*	US-4,698,346	10-06-1987	Musser <i>et al.</i>	
	A16*	US-4,758,574	07-19-1988	Robertson <i>et al.</i>	
	A17*	US-4,774,339	09-27-1988	Haugland <i>et al.</i>	
	A18*	US-4,775,674	10-04-1988	Meanwell <i>et al.</i>	
	A19*	US-4,800,206	01-24-1989	Alig <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B1	AU-2002239547	11-30-2006	3m Innovative Properties Co		
	B2	AU-2004264336-A1	02-24-2005	3m Innovative Properties Co		
	B3	CA-2044087-A1	12-09-1991	Roussel Uclaf		√
	B4	CA-2158996-A1	10-13-1994	Bayer Ag		
	B5	CN-1354663-A	06-19-2002	3m Innovative Properties Co		√
	B6	EP-0 145 340-A2	06-19-1985	Riker Laboratories Inc		

Examiner Signature	/Nilofar Rahmani/	Date Considered	08/24/2010
-----------------------	-------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	2	of	57	Attorney Docket Number	C1271.70021US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A20*	US-4,826,830	05-02-1989	Han <i>et al.</i>	
	A21*	US-4,837,378	06-06-1989	Borgman	
	A22*	US-4,880,779	11-14-1989	Gallaher	
	A23*	US-4,904,669	02-27-1990	Knoll <i>et al.</i>	
	A24*	US-4,988,714	01-29-1991	Alig <i>et al.</i>	
	A25*	US-5,187,288	02-16-1993	Kang <i>et al.</i>	
	A26*	US-5,225,183	07-06-1993	Purewal <i>et al.</i>	
	A27*	US-5,248,782	09-28-1993	Haugland <i>et al.</i>	
	A28*	US-5,274,113	12-28-1993	Kang <i>et al.</i>	
	A29*	US-5,342,784	08-30-1994	Yamada <i>et al.</i>	
	A30*	US-5,352,680	10-04-1994	Portoghese <i>et al.</i>	
	A31*	US-5,376,501	12-27-1994	Marien <i>et al.</i>	
	A32*	US-5,378,848	01-03-1995	Takada <i>et al.</i>	
	A33*	US-5,444,065	08-22-1995	Nikolaides <i>et al.</i>	
	A34*	US-5,446,160	08-29-1995	Stucky <i>et al.</i>	
	A35*	US-5,494,916	02-27-1996	Lindstrom <i>et al.</i>	
	A36*	US-5,500,228	03-19-1996	Lawter <i>et al.</i>	
	A37*	US-5,525,612	06-11-1996	Gerster	
	A38*	US-5,530,114	06-25-1996	Bennett <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> ( <i>if known</i> )				
	B7	EP-0 223 420-A1	05-27-1987	Shionogi & Co		
	B8	EP-0 310 950-A1	04-12-1989	Riker Laboratories Inc		
	B9	EP-0 385 630-A2	09-05-1990	Riker Laboratories Inc		
	B10	EP-0 389 302-A1	09-26-1990	Riker Laboratories Inc		
	B11	EP-0 425 306-A2	05-02-1991	Riker Laboratories Inc		
	B12	EP-0 510 260-A2	10-28-1992	Toyo Jozo Kk		

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
-----------------------	--------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	3	of	57	Attorney Docket Number	C1271.70021US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A39*	US-5,569,450	10-29-1996	Duan <i>et al.</i>	
	A40*	US-5,571,819	11-05-1996	Sabb <i>et al.</i>	
	A41*	US-5,578,727	11-26-1996	Andre <i>et al.</i>	
	A42*	US-5,585,612	12-17-1996	Harp, Jr.	
	A43*	US-5,602,256	02-11-1997	Andre <i>et al.</i>	
	A44*	US-5,605,899	02-25-1997	Gerster <i>et al.</i>	
	A45*	US-5,612,377	03-18-1997	Crooks <i>et al.</i>	
	A46*	US-5,627,281	05-06-1997	Nikolaides <i>et al.</i>	
	A47*	US-5,644,063	07-01-1997	Lindstrom <i>et al.</i>	
	A48*	US-5,648,516	07-15-1997	Nikolaides <i>et al.</i>	
	A49*	US-5,714,608	02-03-1998	Gerster	
	A50*	US-5,731,193	03-24-1998	Mori <i>et al.</i>	
	A51*	US-5,736,553	04-07-1998	Wick <i>et al.</i>	
	A52*	US-5,741,909	04-21-1998	Gerster <i>et al.</i>	
	A53*	US-5,750,134	05-12-1998	Scholz <i>et al.</i>	
	A54*	US-5,776,432	07-07-1998	Schultz <i>et al.</i>	
	A55*	US-5,780,045	07-14-1998	McQuinn <i>et al.</i>	
	A56*	US-5,837,809	11-17-1998	Grandy <i>et al.</i>	
	A57*	US-5,840,744	11-24-1998	Borgman	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B13	EP-0 778 277-A1	06-11-1997	Pfizer		
	B14	EP-0 645 389-A1	03-29-1995	Lonza Ag		√
	B15	EP-0 894 797-A1	02-03-1999	Terumo Corp		
	B16	EP-0 940 629-A2	09-08-1999	Speights Ltd		
	B17	EP-1 082 960-A2	03-14-2001	Pfizer Prod Inc		
	B18	EP-1 097 709-A2	05-09-2001	Pfizer Prod Inc		

Examiner Signature	/Nilofar Rahmani/	Date Considered	08/24/2010
-----------------------	-------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	4	of	57	Attorney Docket Number	C1271.70021US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A58*	US-5,854,257	12-29-1998	Armitage <i>et al.</i>	
	A59*	US-5,861,268	01-19-1999	Tang <i>et al.</i>	
	A60*	US-5,886,006	03-23-1999	Nikolaides <i>et al.</i>	
	A61*	US-5,939,047	08-17-1999	Jernberg	
	A62*	US-5,962,479	10-05-1999	Chen	
	A63*	US-5,962,636	10-05-1999	Bachmaier <i>et al.</i>	
	A64*	US-5,977,366	11-02-1999	Gerster <i>et al.</i>	
	A65*	US-6,028,076	02-22-2000	Hirota <i>et al.</i>	
	A66*	US-6,057,371	05-02-2000	Glennon	
	A67*	US-6,069,140	05-30-2000	Sessler <i>et al.</i>	
	A68*	US-6,071,949	06-06-2000	Mulshine <i>et al.</i>	
	A69*	US-6,077,349	06-20-2000	Kikuchi	
	A70*	US-6,113,918	09-05-2000	Johnson <i>et al.</i>	
	A71*	US-6,121,323	09-19-2000	Merrill	
	A72*	US-6,123,957	09-26-2000	Jernberg	
	A73*	US-6,126,938	10-03-2000	Guy <i>et al.</i>	
	A74*	US-6,194,388	02-27-2001	Krieg <i>et al.</i>	
	A75*	US-6,207,646	03-27-2001	Krieg <i>et al.</i>	
	A76*	US-6,239,116	05-29-2001	Krieg <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B19	EP-1 145 340-A2	10-17-2001	Siemens Westinghouse Power <i>et al.</i>		
	B20	EP-1 256 582-A1	11-13-2002	Hokuriku Pharmaceutical		
	B21	EP-1 341 791-A2	09-10-2003	3m Innovative Properties Co		
	B22	EP-1 495 758-A2	01-12-2005	3m Innovative Properties Co		
	B23	HU-34479-A2	03-28-1985	Egyt Gyogyszervegyeszeti Gyar		✓
	B24	HU-190109-A2	03-28-1985	Egyt Gyogyszervegyeszeti Gyar		✓

Examiner Signature	/Nilofar Rahmani/	Date Considered	08/24/2010
-----------------------	-------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	5	of	57	Attorney Docket Number	C1271.70021US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A77*	US-6,294,271	09-25-2001	Sumita <i>et al.</i>	
	A78*	US-6,303,347	10-16-2001	Johnson <i>et al.</i>	
	A79*	US-6,309,623	10-30-2001	Weers <i>et al.</i>	
	A80*	US-6,315,985	11-13-2001	Wu <i>et al.</i>	
	A81*	US-6,323,200	11-27-2001	Gerster <i>et al.</i>	
	A82*	US-6,329,381	12-11-2001	Kurimoto <i>et al.</i>	
	A83*	US-6,339,068	01-15-2002	Krieg <i>et al.</i>	
	A84*	US-6,348,462	02-19-2002	Gerster <i>et al.</i>	
	A85*	US-6,365,166	04-02-2002	Beaurline <i>et al.</i>	
	A86*	US-6,376,501	04-23-2002	Isobe <i>et al.</i>	
	A87*	US-6,387,383	05-14-2002	Dow <i>et al.</i>	
	A88*	US-6,387,938	05-14-2002	Mizuguchi <i>et al.</i>	
	A89*	US-6,406,705	06-18-2002	Davis <i>et al.</i>	
	A90*	US-6,426,334	07-30-2002	Agrawal <i>et al.</i>	
	A91*	US-6,440,992	08-27-2002	Gerster <i>et al.</i>	
	A92*	US-6,451,485	09-17-2002	James <i>et al.</i>	
	A93*	US-6,465,654	10-15-2002	Gerster <i>et al.</i>	
	A94*	US-6,476,000	11-05-2002	Agrawal	
	A95*	US-6,486,168	11-26-2002	Skwierczynski <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B25	HU-210051-A2	06-28-1991	Riker Laboratories Inc		
	B26	HU-218950-A2	09-28-1995	Shionogi & Co		✓
	B27	IL-73534-A	12-23-1990	Riker Laboratories Inc		✓
	B28	JP-4-066571-A	03-02-1992	Meiji Seika Kaisha		✓
	B29	JP-4-327587-A	11-17-1992	Asahi Chemical Ind		✓
	B30	JP-5-286973-A	11-02-1993	Shionogi & Co		✓

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
-----------------------	--------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	6	of	57	Attorney Docket Number	C1271.70021US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A96*	US-6,486,186	11-26-2002	Fowler <i>et al.</i>	
	A97*	US-6,511,485	01-28-2003	Hirt <i>et al.</i>	
	A98*	US-6,514,985	02-04-2003	Gerster <i>et al.</i>	
	A99*	US-6,518,239	02-11-2003	Kuo <i>et al.</i>	
	A100*	US-6,518,280	02-11-2003	Gerster <i>et al.</i>	
	A101*	US-6,525,028	02-25-2003	Johnson <i>et al.</i>	
	A102*	US-6,541,485	04-01-2003	Crooks <i>et al.</i>	
	A103*	US-6,582,957	06-24-2003	Turner, Jr. <i>et al.</i>	
	A104*	US-6,610,319	08-26-2003	Tomai <i>et al.</i>	
	A105*	US-6,627,638	09-30-2003	Gerster <i>et al.</i>	
	A106*	US-6,627,639	09-30-2003	Stack <i>et al.</i>	
	A107*	US-6,627,640	09-30-2003	Gerster <i>et al.</i>	
	A108*	US-6,630,588	10-07-2003	Rice <i>et al.</i>	
	A109*	US-6,638,944	10-28-2003	Mickelson	
	A110*	US-6,649,172	11-18-2003	Johnson	
	A111*	US-6,660,747	12-09-2003	Crooks <i>et al.</i>	
	A112*	US-6,677,334	01-13-2004	Gerster <i>et al.</i>	
	A113*	US-6,696,076	02-24-2004	Tomai <i>et al.</i>	
	A114*	US-6,703,402	03-09-2004	Gerster <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B31	JP-53-050197-A	05-08-1978	Yoshitomi Pharmaceutical		✓
	B32	JP-63-010787-A	01-18-1988	Takeda Chemical Industries Ltd		✓
	B33	RU-2076105-C1	03-27-1997	Hoechst Ag		✓
	B34	RU-2127273-C1	03-10-1999	Janssen Pharmaceutica Nv		✓
	B35	RU-2221798-C2	01-20-2004			✓
	B36	WO-91/06682-A1	05-16-1991	Pfeifer & Langen		

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
-----------------------	--------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/595,103-Conf. #2609	
			Filing Date	February 14, 2006	
			First Named Inventor	Kyle J. Lindstrom	
			Art Unit	1625	
			Examiner Name	N. Rahmani	
Sheet	7	of	57	Attorney Docket Number	C1271.70021US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A115*	US-6,716,988	04-06-2004	Dellaria <i>et al.</i>	
	A116*	US-6,720,333	04-13-2004	Dellaria <i>et al.</i>	
	A117*	US-6,720,334	04-13-2004	Dellaria <i>et al.</i>	
	A118*	US-6,720,422	04-13-2004	Dellaria <i>et al.</i>	
	A119*	US-6,780,873	08-24-2004	Crooks <i>et al.</i>	
	A120*	US-6,784,188	08-31-2004	Crooks <i>et al.</i>	
	A121*	US-6,790,961	09-14-2004	Gerster <i>et al.</i>	
	A122*	US-6,800,624	10-05-2004	Crooks <i>et al.</i>	
	A123*	US-6,825,350	11-30-2004	Crooks <i>et al.</i>	
	A124*	US-6,855,217	02-15-2005	Suzuki	
	A125*	US-6,855,350	02-15-2005	Lu	
	A126*	US-6,878,719	04-12-2005	Lindstrom <i>et al.</i>	
	A127*	US-6,888,000	05-03-2005	Crooks <i>et al.</i>	
	A128*	US-6,894,060	05-17-2005	Slade	
	A129*	US-6,894,165	05-17-2005	Gerster <i>et al.</i>	
	A130*	US-6,897,221	05-24-2005	Crooks <i>et al.</i>	
	A131*	US-6,900,016	05-31-2005	Venter <i>et al.</i>	
	A132*	US-6,903,113	06-07-2005	Heppner <i>et al.</i>	
	A133*	US-6,916,925	07-12-2005	Rice <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B37	WO-92/01305-A1	01-23-1992	Coloray Display Corp		
	B38	WO-92/06093-A1	04-16-1992	Minnesota Mining & Mfg		
	B40	WO-92/15581-A1	09-17-1992	Minnesota Mining & Mfg		
	B41	WO-92/15582-A1	09-17-1992	Minnesota Mining & Mfg		
	B42	WO-93/05042-A1	03-18-1993	Minnesota Mining & Mfg		

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
-----------------------	--------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	8	of	57	Attorney Docket Number	C1271.70021US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A134*	US-6,921,826	07-26-2005	Dellaria <i>et al.</i>	
	A135*	US-6,924,293	08-02-2005	Lindstrom	
	A136*	US-6,943,240	09-13-2005	Bauer <i>et al.</i>	
	A137*	US-6,943,255	09-13-2005	Lindstrom <i>et al.</i>	
	A138*	US-6,949,649	09-27-2005	Bonk <i>et al.</i>	
	A139*	US-6,953,804	10-11-2005	Dellaria <i>et al.</i>	
	A140*	US-6,969,722	11-29-2005	Heppner <i>et al.</i>	
	A141*	US-6,989,389	01-24-2006	Heppner <i>et al.</i>	
	A142*	US-7,030,129	04-18-2006	Miller <i>et al.</i>	
	A143*	US-7,030,131	04-18-2006	Crooks <i>et al.</i>	
	A144*	US-7,038,053	05-02-2006	Lindstrom <i>et al.</i>	
	A145*	US-7,049,439	05-23-2006	Crooks <i>et al.</i>	
	A146*	US-7,078,253	07-18-2006	Brunner <i>et al.</i>	
	A147*	US-7,078,523	07-18-2006	Crooks <i>et al.</i>	
	A148*	US-7,091,214	08-15-2006	Hays <i>et al.</i>	
	A149*	US-7,098,221	08-29-2006	Heppner <i>et al.</i>	
	A150*	US-7,112,677	09-26-2006	Griesgraber	
	A151*	US-7,115,622	10-03-2006	Crooks <i>et al.</i>	
	A152*	US-7,125,890	10-24-2006	Dellaria <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B43	WO-93/09119-A1	05-13-1993	Minnesota Mining & Mfg		
	B44	WO-93/20847-A1	10-28-1993	Minnesota Mining & Mfg		
	B45	WO-94/10171-A1	05-11-1994	Pfizer <i>et al.</i>		
	B46	WO-95/02597-A1	01-26-1995	Minnesota Mining & Mfg		
	B47	WO-95/02598-A1	01-26-1995	Minnesota Mining & Mfg		
	B48	WO-96/11199-A1	04-18-1995	Knoll Ag <i>et al.</i>		
	B49	WO-96/21663-A1	07-18-1996	Minnesota Mining & Mfg		

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
-----------------------	--------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	9	of	57	Attorney Docket Number	C1271.70021US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A153*	US-7,132,429	11-07-2006	Griesgraber <i>et al.</i>	
	A154*	US-7,179,253	02-20-2007	Graham <i>et al.</i>	
	A155*	US-7,199,131	04-03-2007	Lindstrom	
	A156*	US-7,214,675	05-08-2007	Griesgraber	
	A157*	US-7,220,758	05-22-2007	Dellaria <i>et al.</i>	
	A158*	US-7,226,928	06-05-2007	Mitra <i>et al.</i>	
	A159*	US-7,276,515	10-02-2007	Dellaria <i>et al.</i>	
	A160*	US-7,288,550	10-30-2007	Dellaria <i>et al.</i>	
	A161*	US-7,375,180	05-20-2008	Gorden <i>et al.</i>	
	A162*	US-7,387,271	06-17-2008	Noelle <i>et al.</i>	
	A163*	US-7,393,859	07-01-2008	Coleman <i>et al.</i>	
	A164*	US-7,427,629	09-23-2008	Kedl <i>et al.</i>	
	A165*	US-7,544,697	06-09-2009	Hays <i>et al.</i>	
	A166*	US-7,598,382	10-06-2009	Hays <i>et al.</i>	
	A167*	US-7,612,083	11-03-2009	Griesgraber	
	A168*	US-7,648,997	01-19-2010	Kshirsagar <i>et al.</i>	
	A169*	US-2001-0046968	11-29-2001	Zagon <i>et al.</i>	
	A170*	US-2002-0137101	09-26-2002	Meyers	
	A171*	US-2002-0173655	11-21-2002	Dellaria <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B50	WO-97/48703-A1	12-24-1997	Minnesota Mining & Mfg		
	B51	WO-97/48704-A1	12-24-1997	Minnesota Mining & Mfg		
	B52	WO-98/17279-A1	04-30-1998	Minnesota Mining & Mfg		
	B53	WO-98/30562-A1	07-16-1998	Terumo Corp <i>et al.</i>		√
	B54	WO-98/48805-A1	11-05-1998	Sumitomo Pharma <i>et al.</i>		
	B55	WO-98/50547-A2	11-12-1998	Schering Corp		

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
-----------------------	--------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.15 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	10	of	57	Attorney Docket Number	C1271.70021US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A172*	US-2002-0193729	12-19-2002	Cormier <i>et al.</i>	
	A173*	US-2003-0022302	01-30-2003	Lewis <i>et al.</i>	
	A174*	US-2003-0044429	03-06-2003	Aderem <i>et al.</i>	
	A175*	US-2003-0082108	05-01-2003	Mulshine <i>et al.</i>	
	A176*	US-2003-0088102	05-08-2003	Matsubara <i>et al.</i>	
	A177*	US-2003-0096998	05-22-2003	Gerster <i>et al.</i>	
	A178*	US-2003-0133733	07-17-2003	Korhonen	
	A179*	US-2003-0144283	07-31-2003	Coleman <i>et al.</i>	
	A180*	US-2003-0172391	09-11-2003	Turner <i>et al.</i>	
	A181*	US-2003-0185835	10-02-2003	Braun	
	A182*	US-2003-0199461	10-23-2003	Averett <i>et al.</i>	
	A183*	US-2003-0212092	11-13-2003	Heppner <i>et al.</i>	
	A184*	US-2003-0216481	11-20-2003	Jia	
	A185*	US-2003-0232074	12-18-2003	Lipford <i>et al.</i>	
	A186*	US-2003-0232763	12-18-2003	Jia	
	A187*	US-2003-0232852	12-18-2003	Lindstrom <i>et al.</i>	
	A188*	US-2004-0010007	01-15-2004	Dellaria <i>et al.</i>	
	A189*	US-2004-0023870	02-05-2004	Dedera <i>et al.</i>	
	A190*	US-2004-0067975	04-08-2004	Crooks <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B56	WO-98/54226-A1	12-03-1998	Pastoral Agric Res Inst Nz Ltd <i>et al.</i>		
	B57	WO-99/18105-A1	04-15-1999	Ortho Mcneil Pharm Inc		
	B58	WO-99/29693-A1	06-17-1999	Minnesota Mining & Mfg		
	B59	WO-00/06577-A1	02-10-2000	3m Innovative Properties Co		
	B60	WO-00/09506-A1	02-24-2000	Hokuriku Pharmaceutical <i>et al.</i>		v
	B61	WO-00/19987-A1	04-13-2000	3m Innovative Properties Co <i>et al.</i>		

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
-----------------------	--------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	11	of	57	Attorney Docket Number	C1271.70021US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A191*	US-2004-0072858	04-15-2004	Charles <i>et al.</i>	
	A192*	US-2004-0076633	04-22-2004	Thomsen <i>et al.</i>	
	A193*	US-2004-0092545	05-13-2004	Crooks <i>et al.</i>	
	A194*	US-2004-0097542	05-20-2004	Crooks <i>et al.</i>	
	A195*	US-2004-0106638	06-03-2004	Lindstrom	
	A196*	US-2004-0132748	07-08-2004	Isobe <i>et al.</i>	
	A197*	US-2004-0132766	07-08-2004	Griesgraber	
	A198*	US-2004-0157874	08-12-2004	Crooks <i>et al.</i>	
	A199*	US-2004-0167157	08-26-2004	Masui <i>et al.</i>	
	A200*	US-2004-0175336	09-09-2004	Egging <i>et al.</i>	
	A201*	US-2004-0204436	10-14-2004	Gerster <i>et al.</i>	
	A202*	US-2004-0258698	12-23-2004	Wightman <i>et al.</i>	
	A203*	US-2004-0265351	12-30-2004	Miller <i>et al.</i>	
	A204*	US-2005-0009858	01-13-2005	Martinez-Colon <i>et al.</i>	
	A205*	US-2005-0032829	02-10-2005	Lindstrom <i>et al.</i>	
	A206*	US-2005-0048072	03-03-2005	Kedl <i>et al.</i>	
	A207*	US-2005-0054640	03-10-2005	Griesgraber <i>et al.</i>	
	A208*	US-2005-0054665	03-10-2005	Miller <i>et al.</i>	
	A209*	US-2005-0059072	03-17-2005	Birmachu <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B62	WO-00/40228-A2	07-13-2000	3m Innovative Properties Co		
	B63	WO-00/47719-A2	08-17-2000	3m Innovative Properties Co		
	B64	WO-00/75304-A1	12-14-2000	Aventis Pasteur <i>et al.</i>		√
	B65	WO-00/76505-A1	12-21-2000	3m Innovative Properties Co		
	B66	WO-00/76518-A1	12-21-2000	3m Innovative Properties Co		
	B67	WO-01/34709-A1	05-17-2001	3m Innovative Properties Co		

Examiner Signature	/Nilofar Rahmani/	Date Considered	08/24/2010
-----------------------	-------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	12	of	57	Attorney Docket Number	C1271.70021US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A210*	US-2005-0070460	03-31-2005	Hammerbeck <i>et al.</i>	
	A211*	US-2005-0096259	05-05-2005	Tomai <i>et al.</i>	
	A212*	US-2005-0119273	06-02-2005	Lipford <i>et al.</i>	
	A213*	US-2005-0136065	06-23-2005	Valiante	
	A214*	US-2005-0148620	07-07-2005	Crooks <i>et al.</i>	
	A215*	US-2005-0158325	07-21-2005	Hammerbeck <i>et al.</i>	
	A216*	US-2005-0171072	08-04-2005	Tomai <i>et al.</i>	
	A217*	US-2005-0226878	10-13-2005	Tomai <i>et al.</i>	
	A218*	US-2005-0234088	10-20-2005	Griesgraber	
	A219*	US-2005-0239733	10-27-2005	Jurk <i>et al.</i>	
	A220*	US-2005-0239735	10-27-2005	Miller <i>et al.</i>	
	A221*	US-2005-0267145	12-01-2005	Merrill <i>et al.</i>	
	A222*	US-2005-0281813	12-22-2005	Dedera <i>et al.</i>	
	A223*	US-2006-0009482	01-12-2006	Tomai <i>et al.</i>	
	A224*	US-2006-0100229	05-11-2006	Hays <i>et al.</i>	
	A225*	US-2006-0106052	05-18-2006	Crooks <i>et al.</i>	
	A226*	US-2007-0066639	03-22-2007	Kshirsagar <i>et al.</i>	
	A227*	US-2007-0072893	03-29-2007	Krepski <i>et al.</i>	
	A228*	US-2007-0099901	05-03-2007	Krepski <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B68	WO-01/51486-A2	07-19-2001	Byk Gulden Lomberg Chem Fab <i>et al.</i>		
	B69	WO-01/55439-A1	08-02-2001	Progenics Pharm Inc		
	B70	WO-01/58900-A1	08-16-2001	Hokuriku Pharmaceutical <i>et al.</i>		✓
	B71	WO-01/74343-A2	10-11-2001	3m Innovative Properties Co		
	B72	WO-01/74821-A1	10-11-2001	Shionogi & Co <i>et al.</i>		✓
	B73	WO-02/07725-A1	01-31-2002	Alteon Inc		

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
-----------------------	--------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	13	of	57	Attorney Docket Number	C1271.70021US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A229*	US-2007-0155767	07-05-2007	Radmer <i>et al.</i>	
	A230*	US-2007-0167476	07-19-2007	Kshirsagar <i>et al.</i>	
	A231*	US-2007-0208052	09-06-2007	Prince <i>et al.</i>	
	A232*	US-2007-0213356	09-13-2007	Merrill <i>et al.</i>	
	A233*	US-2007-0219196	09-20-2007	Krepski <i>et al.</i>	
	A234*	US-2007-0219228	09-20-2007	Niwas <i>et al.</i>	
	A235*	US-2007-0259881	11-08-2007	Dellaria <i>et al.</i>	
	A236*	US-2007-0259907	11-08-2007	Prince	
	A237*	US-2007-0287725	12-13-2007	Miser <i>et al.</i>	
	A238*	US-2007-0292456	12-20-2007	Hammerbeck <i>et al.</i>	
	A239*	US-2008-0015184	01-17-2008	Kshirsagar <i>et al.</i>	
	A240*	US-2008-0070907	03-20-2008	Griesgraber <i>et al.</i>	
	A241*	US-2008-0085895	04-10-2008	Griesgraber <i>et al.</i>	
	A242*	US-2008-0114019	05-15-2008	Kshirsagar <i>et al.</i>	
	A243*	US-2008-0119508	05-22-2008	Slade <i>et al.</i>	
	A244*	US-2008-0207674	08-28-2008	Stoesz <i>et al.</i>	
	A245*	US-2008-0269192	10-30-2008	Griesgraber <i>et al.</i>	
	A246*	US-2008-0306252	12-11-2008	Crooks <i>et al.</i>	
	A247*	US-2008-0312434	12-18-2008	Lindstrom <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B74	WO-02/22809-A2	03-21-2002	Coley Pharm Gmbh <i>et al.</i>		
	B75	WO-02/24225-A1	03-28-2002	Glaxo Group Ltd <i>et al.</i>		
	B76	WO-02/46188-A2	06-13-2002	3m Innovative Properties Co <i>et al.</i>		
	B77	WO-02/46189-A2	06-13-2002	3m Innovative Properties Co <i>et al.</i>		
	B78	WO-02/46190-A2	06-13-2002	3m Innovative Properties Co <i>et al.</i>		
	B79	WO-02/46191-A2	06-13-2002	3m Innovative Properties Co <i>et al.</i>		

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
-----------------------	--------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete If Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	14	of	57	Attorney Docket Number	C1271.70021US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A248*	US-2008-0318998	12-25-2008	Prince <i>et al.</i>	
	A249*	US-2009-0005371	01-01-2009	Rice <i>et al.</i>	
	A250*	US-2009-0017076	01-15-2009	Miller <i>et al.</i>	
	A251*	US-2009-0018122	01-15-2009	Lindstrom <i>et al.</i>	
	A252*	US-2009-0023722	01-22-2009	Coleman <i>et al.</i>	
	A253*	US-2009-0029988	01-29-2009	Kshirsagar <i>et al.</i>	
	A254*	US-2009-0030030	01-29-2009	Bonk <i>et al.</i>	
	A255*	US-2009-0030031	01-29-2009	Kshirsagar <i>et al.</i>	
	A256*	US-2009-0042925	02-12-2009	Kshirsagar <i>et al.</i>	
	A257*	US-2009-0062272	03-05-2009	Bonk <i>et al.</i>	
	A258*	US-2009-0062328	03-05-2009	Kshirsagar <i>et al.</i>	
	A259*	US-2009-0069299	03-12-2009	Merrill <i>et al.</i>	
	A260*	US-2009-0069314	03-12-2009	Kshirsagar <i>et al.</i>	
	A261*	US-2009-0075980	03-19-2009	Hays <i>et al.</i>	
	A262*	US-2009-0099161	04-16-2009	Rice <i>et al.</i>	
	A263*	US-2009-0105295	04-23-2009	Kshirsagar <i>et al.</i>	
	A264*	US-2009-0124611	05-14-2009	Hays <i>et al.</i>	
	A265*	US-2009-0163532	06-25-2009	Perman <i>et al.</i>	
	A266*	US-2009-0163533	06-25-2009	Hays <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B80	WO-02/46192-A2	06-13-2002	3m Innovative Properties Co <i>et al.</i>		
	B81	WO-02/85905-A1	10-31-2002	Japan Energy Corp <i>et al.</i>		✓
	B82	WO-03/08421-A1	01-30-2003	Shionogi & Co <i>et al.</i>		✓
	B83	WO-03/09852-A1	02-06-2003	Merck & Co Inc <i>et al.</i>		
	B84	WO-03/103584-A2	12-18-2003	3m Innovative Properties Co		
	B85	WO-03/45494-A2	06-05-2003	Martinez-colon Maria		

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
-----------------------	--------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
				Attorney Docket Number	C1271.70021US02
Sheet	15	of	57		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B86	WO-03/45929-A1	06-05-2003	Takeda Chemical Industries Ltd <i>et al.</i>		√
	B87	WO-03/50117-A1	06-19-2003	3m Innovative Properties Co		
	B88	WO-03/50118-A1	06-19-2003	3m Innovative Properties Co		
	B89	WO-03/50119-A2	06-19-2003	3m Innovative Properties Co <i>et al.</i>		
	B90	WO-03/77944-A1	09-25-2003	Glaxo Group Ltd <i>et al.</i>		
	B91	WO-03/80114-A2	10-02-2003	Powderject Res Ltd <i>et al.</i>		

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
--------------------	--------------------	-----------------	------------

**EXAMINER:** Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
--------------------	--------------------	-----------------	------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <h1>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h1>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
				Attorney Docket Number	C1271.70021US02
Sheet	18	of	57		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>2</sup> -Number <sup>4</sup> -Kind Code <sup>3</sup> (if known)				
	B104	WO-2004/110991-A2	12-23-2004	3m Innovative Properties Co <i>et al.</i>		
	B105	WO-2004/110992-A2	12-23-2004	3m Innovative Properties Co <i>et al.</i>		
	B106	WO-2005/003064-A2	01-13-2005	3m Innovative Properties Co		
	B107	WO-2005/003065-A2	01-13-2005	3m Innovative Properties Co		
	B108	WO-2005/016273-A2	02-24-2005	3m Innovative Properties Co		
	B109	WO-2005/016275-A2	02-24-2005	3m Innovative Properties Co <i>et al.</i>		

Examiner Signature	/Nilofar Rahmani/	Date Considered	08/24/2010
-----------------------	-------------------	--------------------	------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
--------------------	--------------------	-----------------	------------

**EXAMINER:** Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <h1>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h1>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
				Attorney Docket Number	C1271.70021US02
Sheet	20	of	57		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	† <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (# known)				
	B116	WO-2005/065678-A1	07-21-2005	3m Innovative Properties Co		
	B117	WO-2005/067500-A2	07-28-2005	3m Innovative Properties Co		
	B118	WO-2006/004737-A2	01-12-2006	Purdue Research Foundation <i>et al.</i>		
	B119	WO-2006/063072-A2	06-15-2006	3m Innovative Properties Co <i>et al.</i>		
	B120	WO-2006/063152-A2	06-15-2006	3m Innovative Properties Co <i>et al.</i>		
	B121	WO-2006/065280-A2	06-22-2006	3m Innovative Properties Co <i>et al.</i>		

Examiner Signature	/Niloufar Bahmani/	Date Considered	08/24/2010
--------------------	--------------------	-----------------	------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete If Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
				Attorney Docket Number	C1271.70021US02
Sheet	21	of	57		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B122	WO-2006/073940-A2	07-13-2006	3m Innovative Properties Co <i>et al.</i>		
	B123	WO-2006/074003-A2	07-13-2006	3m Innovative Properties Co <i>et al.</i>		
	B124	WO-2006/074045-A2	07-13-2006	3m Innovative Properties Co <i>et al.</i>		
	B125	WO-2006/083440-A2	08-10-2006	3m Innovative Properties Co <i>et al.</i>		
	B126	WO-2006/084251-A2	08-10-2006	3m Innovative Properties Co <i>et al.</i>		
	B127	WO-2006/086449-A2	08-17-2006	3m Innovative Properties Co <i>et al.</i>		

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
-----------------------	--------------------	--------------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
				Attorney Docket Number	C1271.70021US02
Sheet	22	of	57		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	Page Number
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (# known)				
	B128	WO-2006/086633-A2	08-17-2006	3m Innovative Properties Co <i>et al.</i>		
	B129	WO-2006/086634-A2	08-17-2006	3m Innovative Properties Co <i>et al.</i>		
	B130	WO-2006/091394-A2	08-31-2006	3m Innovative Properties Co <i>et al.</i>		
	B131	WO-2006/091567-A2	08-31-2006	3m Innovative Properties Co <i>et al.</i>		
	B132	WO-2006/091568-A2	08-31-2006	3m Innovative Properties Co <i>et al.</i>		
	B133	WO-2006/091647-A2	08-31-2006	3m Innovative Properties Co <i>et al.</i>		

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
-----------------------	--------------------	--------------------	------------

**EXAMINER:** Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
				Attorney Docket Number	C1271.70021US02
Sheet	23	of	57		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>o</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B134	WO-2006/093514-A2	09-08-2006	3m Innovative Properties Co <i>et al.</i>		
	B135	WO-2006/098852-A2	09-21-2006	3m Innovative Properties Co <i>et al.</i>		
	B136	WO-2006/107753-A2	10-12-2006	3m Innovative Properties Co		
	B137	WO-2006/107771-A2	10-12-2006	3m Innovative Properties Co <i>et al.</i>		
	B138	WO-2006/107851-A1	10-12-2006	3m Innovative Properties Co <i>et al.</i>		
	B139	WO-2006/107853-A2	10-12-2006	3m Innovative Properties Co <i>et al.</i>		

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
-----------------------	--------------------	--------------------	------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
				Attorney Docket Number	C1271.70021US02
Sheet	24	of	57		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B140	WO-2006/121528-A2	11-16-2006	3m Innovative Properties Co <i>et al.</i>		
	B141	WO-2006/122806-A2	11-23-2006	Novartis Ag <i>et al.</i>		
	B142	WO-2007/028129-A1	03-08-2007	3m Innovative Properties Co <i>et al.</i>		
	B143	WO-2007/030775-A2	03-15-2007	3m Innovative Properties Co <i>et al.</i>		
	B144	WO-2007/030777-A2	03-15-2007	3m Innovative Properties Co <i>et al.</i>		
	B145	WO-2007/035935-A1	03-29-2007	3m Innovative Properties Co <i>et al.</i>		

Examiner Signature	<i>/Niloofer Bahmani/</i>	Date Considered	08/24/2010
--------------------	---------------------------	-----------------	------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <h1>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h1>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
				Attorney Docket Number	C1271.70021US02
Sheet	25	of	57		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (# known)				
	B146	WO-2007/056112-A2	05-18-2007	3m Innovative Properties Co <i>et al.</i>		
	B147	WO-2007/062043-A1	05-31-2007	3m Innovative Properties Co <i>et al.</i>		
	B148	WO-2007/075468-A1	07-05-2007	3m Innovative Properties Co <i>et al.</i>		
	B149	WO-2007/079086-A1	07-12-2007	3m Innovative Properties Co <i>et al.</i>		
	B150	WO-2007/079146-A1	07-12-2007	3m Innovative Properties Co <i>et al.</i>		
	B151	WO-2007/079169-A2	07-12-2007	3m Innovative Properties Co <i>et al.</i>		

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
-----------------------	--------------------	--------------------	------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

Sheet	26	of	57
-------	----	----	----

**Complete If Known**

Application Number	10/595,103-Conf. #2609
--------------------	------------------------

<b>Filing Date</b>	<b>February 14, 2006</b>
--------------------	--------------------------

First Named Inventor	Kyle J. Lindstrom
----------------------	-------------------

Art Unit	1625
----------	------

Examiner Name	N. Rahmani
---------------	------------

Attorney Docket Number	C1271.70021US02
------------------------	-----------------

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	Page #
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (# known)				
	B152	WO-2007/079171-A2	07-12-2007	3m Innovative Properties Co <i>et al.</i>		
	B153	WO-2007/079202-A2	07-12-2007	3m Innovative Properties Co <i>et al.</i>		
	B154	WO-2007/079203-A2	07-12-2007	3m Innovative Properties Co <i>et al.</i>		
	B155	WO-2007/092641-A2	08-16-2007	3m Innovative Properties Co <i>et al.</i>		
	B156	WO-2007/106852-A2	09-20-2007	3m Innovative Properties Co <i>et al.</i>		
	B157	WO-2007/106854-A2	09-20-2007	3m Innovative Properties Co <i>et al.</i>		

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
-----------------------	--------------------	--------------------	------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <h1>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h1>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
				Attorney Docket Number	C1271.70021US02
Sheet	27	of	57		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			
	B158	WO-2007/120121-A2	10-25-2007	Coley Pharm Group Inc <i>et al.</i>		
	B159	WO-2007/143526-A2	12-13-2007	Coley Pharm Group Inc <i>et al.</i>		
	B160	WO-2008/008432-A2	01-17-2008	Coley Pharm Group Inc <i>et al.</i>		
	B161	WO-2008/030511-A2	03-13-2008	Coley Pharmaceutical Group Inc <i>et al.</i>		
	B162	WO-2008/036312-A1	03-27-2008	Coley Pharm Group Inc <i>et al.</i>		
	B163	WO-2008/045543-A1	04-17-2008	Coley Pharm Group Inc <i>et al.</i>		

Examiner Signature	/Nilofar Rahmani/	Date Considered	08/24/2010
--------------------	-------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	28	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	[NO AUTHOR LISTED] "Comparative Tests." Filed April 8, 2005 during prosecution for EP 00938205.2, EP 00950215.4 and EP 00938211.0 in the name of 3M Innovative Properties Co.	
	C2	[NO AUTHOR LISTED] Chemical Abstracts. 1964;61(1):6060g.	
	C3	[NO AUTHOR LISTED] Encyclopedia of Pharmaceutical Technology. 2nd Ed. Marcel Dekker, Inc. 2002:856-60.	
	C4	AGRAWAL <i>et al.</i> , Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem Soc Trans. 2007 Dec;35(Pt 6):1461-7.	
	C5	AHMED <i>et al.</i> , A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods. 1994 Apr 15;170(2):211-24.	
	C6	AKIRA <i>et al.</i> , Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett. 2003;85:85-95.	
	C7	AKIRA <i>et al.</i> , Toll-like receptors: critical proteins linking innate and acquired immunity. Nature Immunol. 2001;2(8):675-80	
	C8	ALEXOPOULOU <i>et al.</i> , Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001 Oct 18;413(6857):732-8.	
	C9	ASSUMA <i>et al.</i> , IL-1 and TNF Antagonists Inhibit the Inflammatory Response and Bone Loss in Experimental Periodontitis. J Immunol. 2000;160:403-09.	
	C10	AU <i>et al.</i> , Virus-mediated induction of interferon A gene requires cooperation between multiple binding factors in the interferon alpha promoter region. J Biol Chem. 1993 Nov 15;268(32):24032-40.	

Examiner Signature	/Nilloofar Rahmani/	Date Considered	08/24/2010
-----------------------	---------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/595,103-Conf. #2609	
			Filing Date	February 14, 2006	
			First Named Inventor	Kyle J. Lindstrom	
			Art Unit	1625	
			Examiner Name	N. Rahmani	
Sheet	29	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C11	AUERBACH <i>et al.</i> , Erythema nodosum following a jellyfish sting. J Emerg Med. 1987 Nov-Dec;5(6):487-91.	
	C12	AUWERS, [Über die Isomerie-Verhältnisse in der Pyrazol-Reihe. Berichte. VI.] 1926;601-607. German	
	C13	BAFFIS <i>et al.</i> , Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection. Ann Intern Med. 1999 Nov 2;131(9):696-701.	
	C14	BAKER <i>et al.</i> , Oral infection with Porphyromonas gingivalis and induced alveolar bone loss in immunocompetent and severe combined immunodeficient mice. Arch Oral Biol. 1994 Dec;39(12):1035-40.	
	C15	BALDWIN <i>et al.</i> , Amino Acid Synthesis via Ring Opening of N-Sulphonyl Aziridine-2-Carboxylate Esters with Organometallic Reagents. Tetrahedron. 1993;49:6309-30.	
	C16	BÁRTOVÁ <i>et al.</i> , Th1 and Th2 cytokine profile in patients with early onset periodontitis and their healthy siblings. Mediators Inflamm. 2000;9(2):115-20.	
	C17	BECK <i>et al.</i> , Dental Infections and Atherosclerosis. Am Heart J. 1999;13:528-33.	
	C18	BECKETT <i>et al.</i> , Configurational Studies in Synthetic Analgesics: the Synthesis of (-)-Methadone from D-(-)- Alanine. J Chem Soc. 1957;1:858-61.	
	C19	BEILMAN <i>et al.</i> , Experimental brown spider bite in the guinea pig: Results of treatment with dapsone or hyperbaric oxygen. J Wilderness Medicine. 1994;5:287-94.	
	C20	BELIKOV, Abbreviated Guide to Synthetic and Natural Medications. Pharmaceutical Chemistry. Higher School. 1993;1:43-47. Russian.	✓

Examiner Signature	/Niloofer Bahmani/	Date Considered	08/24/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	30	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C21	BELTRAMI <i>et al.</i> , Some Methylhydrazonium Salts; An Improved Synthesis of Tetramethylhydrazine. J Am Chem Soc. 1956;1956:2467-68.	
	C22	BERNSTEIN <i>et al.</i> , Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment. J Infect Dis. 2001 Mar 15;183(6):844-9. Epub 2001 Feb 13.	
	C23	BERTINO <i>et al.</i> , Principles of Cancer Therapy. Cecil Textbook of Medicine. Goldman <i>et al.</i> , eds. 21th Ed. W.B. Saunders Company. 2000:1:1060-74.	
	C24	BEUTLER <i>et al.</i> , Tumor necrosis factor in the pathogenesis of infectious diseases. Crit Care Med. 1993 Oct;21(10 Suppl):S423-35.	
	C25	BEUTNER <i>et al.</i> , Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol. 1999 Dec;41(6):1002-7.	
	C26	BEUTNER <i>et al.</i> , Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol. 1998 Feb;38(2 Pt 1):230-9.	
	C27	BINDER, Acute arthropod envenomation. Incidence, clinical features and management. Med Toxicol Adverse Drug Exp. 1989 May-Jun;4(3):163-73.	
	C28	BISHOP <i>et al.</i> , Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848. J Immunol. 2000 Nov 15;165(10):5552-7.	
	C29	BITTERMAN-DEUTSCH <i>et al.</i> , [Brown spider bite]. Harefuah. 1990 Sep;119(5-6):137-9. Hebrew.	✓
	C30	BOOTH <i>et al.</i> , Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol. 1992 Feb;98(2):135-40.	

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	31	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C31	BORKAN <i>et al.</i> , An outbreak of venomous spider bites in a citrus grove. Am J Trop Med Hyg. 1995 Mar;52(3):228-30.	
	C32	BOURKE <i>et al.</i> , The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood. 2003 Aug 1;102(3):956-63. Epub 2003 Apr 10.	
	C33	BRANTS, The Distribution of Tobacco Mosaic Virus (TMV) in Excised Tomato Roots Cultivated in Vitro. Tijdschr Plantenziekten, 1962;68:198-207.	
	C34	BRASSARD <i>et al.</i> , Interferon- $\alpha$ as an immunotherapeutic protein. J Leukoc Biol. 2002 Apr;71(4):565-81.	
	C35	BREATHNACH, Azelaic acid: potential as a general antitumoural agent. Med Hypotheses. 1999 Mar;52(3):221-6.	
	C36	BROUGHTON, Management of the brown recluse spider bite to the glans penis. Mil Med. 1996 Oct;161(10):627-9.	
	C37	BUCKLE <i>et al.</i> , 4-hydroxy-3-nitro-2-quinolones and related compounds as inhibitors of allergic reactions. J Med Chem. 1975 Jul;18(7):726-32.	
	C38	BUISSON <i>et al.</i> , Preparation and use of (S)-O-acetyllactyl chloride (Mosandl's reagent) as a chiral derivatizing agent. Tetrahedron Assym. 1999;10:2997-3002.	
	C39	BULUT <i>et al.</i> , Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling. J Immunol. 2001 Jul 15;167(2):987-94.	
	C40	BURLESON, Chapter 14. Influenza Virus Host Resistance Model for Assessment of Immunostimulation, and Antiviral Compounds. Methods in Immunology. 1995;2:181-202.	

Examiner Signature	/Nilofar Rahmani/	Date Considered	08/24/2010
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	32	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C41	BUSCHLE <i>et al.</i> , Interferon $\gamma$ inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med. 1993 Jan 1;177(1):213-8.	
	C42	CAI <i>et al.</i> , Evaluation of trifluoroacetic acid as an ion-pair reagent in the separation of small ionizable molecules by reversed-phase liquid chromatography. Analytica Chmica Acta. 1999;399:249-258	
	C43	CANTELL <i>et al.</i> , IFN- $\gamma$ Enhances Production of IFN- $\alpha$ in Human Macrophages but Not in Monocytes. J Interferon and Cytokine Res. 1996;16:461-63.	
	C44	CARCELLER <i>et al.</i> , Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists. J Med Chem. 1996 Jan 19;39(2):487-93.	
	C45	CARRIGAN <i>et al.</i> , Synthesis and in vitro pharmacology of substituted quinoline-2,4-dicarboxylic acids as inhibitors of vesicular glutamate transport. J Med Chem. 2002 May 23;45(11):2260-76.	
	C46	CATARZI <i>et al.</i> , Tricyclic heteroaromatic systems. Pyrazolo[3,4-c]quinolin-4-ones and pyrazolo[3,4-c]quinoline-1,4-diones: synthesis and benzodiazepine receptor activity. Arch Pharm (Weinheim). 1997 Dec;330(12):383-6.	
	C47	CHESON <i>et al.</i> , National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996 Jun 15;87(12):4990-7.	
	C48	CHUANG <i>et al.</i> , Toll-like receptor 9 mediates CpG-DNA signaling. J Leukoc Biol. 2002 Mar;71(3):538-44.	
	C49	CLAISEN, [Uber $\alpha$ -Methyl-isoxazol.] Berichte. 1909;42:59-69. German.	
	C50	COHEN <i>et al.</i> , Cytokine function: a study in biologic diversity. Am J Clin Pathol. 1996 May;105(5):589-98.	

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	33	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	C51	COLE <i>et al.</i> , Brown recluse spider envenomation of the eyelid: an animal model. Ophthal Plast Reconstr Surg. 1995 Sep;11(3):153-64.		
	C52	COLOTTA <i>et al.</i> , Synthesis and structure-activity relationships of a new set of 2-arylpyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists. J Med Chem. 2000 Aug 10;43(16):3118-24.		
	C53	CRISTALLI <i>et al.</i> , Adenosine deaminase inhibitors: synthesis and structure-activity relationships of imidazole analogues of erythro-9-(2-hydroxy-3-nonyl)adenine. J Med Chem. 1991 Mar;34(3):1187-92.		
	C54	DAI <i>et al.</i> , Synthesis of a novel C2-symmetric thiourea and its application in the Pd-catalyzed cross-coupling reactions with arenediazonium salts under aerobic conditions. Org Lett. 2004 Jan 22;6(2):221-4.		
	C55	DAVIS, Current therapy for chronic hepatitis C. Gastroenterology. 2000 Feb;118(2 Suppl 1):S104-14.		
	C56	DAVIS <i>et al.</i> , Heterocyclic Syntheses with Malonyl Chloride. Part VI. 3-Substituted Pyridine Derivatives from $\alpha$ -Methylene-nitriles. J Chem Soc. 1962:3638-44.		
	C57	DAVIS <i>et al.</i> , Self-administered topical imiquimod treatment of vulvar intraepithelial neoplasia. A report of four cases. J Reprod Med. 2000 Aug;45(8):619-23.		
	C58	DE CLERQ, Synthetic interferon inducers. Top Curr Chem. 1974;52:173-208.		
	C59	DE <i>et al.</i> , Structure-activity relationships for antiparasitic activity among 7-substituted 4-aminoquinolines. J Med Chem. 1998 Dec 3;41(25):4918-26.		
	C60	DEBOL <i>et al.</i> , Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol. 1997 Dec;62(6):827-36.		

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	34	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C61	DECKER <i>et al.</i> , Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. <i>Blood</i> . 2000 Feb 1;95(3):999-1006.	
	C62	DECKER <i>et al.</i> , Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype. <i>Exp Hematol</i> . 2000 May;28(5):558-68.	
	C63	DELGADO, Textbook of Organic Medicinal and Pharmaceutical Chemistry, Ninth Edition, Remers, ed., 1991:30-1.	
	C64	DENZEL <i>et al.</i> Imidazo [4,5-c]- and [4,5-b]pyridines. <i>J. Heterocyclic Chem.</i> 1977;14:813-821.	
	C65	DI CARLO <i>et al.</i> , Neutrophils in anti-cancer immunological strategies: old players in new games. <i>J Hematother Stem Cell Res</i> . 2001 Dec;10(6):739-48.	
	C66	DIAZ-ARRASTIA <i>et al.</i> , Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5%. <i>Clin Cancer Res</i> . 2001 Oct;7(10):3031-3.	
	C67	DICKEN <i>et al.</i> , Reactions at High Pressures. [3 + 2] Dipolar Cycloaddition of Nitrones with Vinyl Ethers. <i>J Org Chem</i> . 1982;47:2047-51.	
	C68	DOCKRELL <i>et al.</i> , Imiquimod and resiquimod as novel immunomodulators. <i>J Antimicrob Chemother</i> . 2001 Dec;48(6):751-5.	
	C69	DOUGLAS, Introduction to Viral Diseases. In: Cecil Textbook of Medicine. Bennet <i>et al.</i> , eds. 20th Ed. W.B. Saunders Company. 1996:2:1739-47.	
	C70	DOYLE <i>et al.</i> , Toll-like receptor 3 mediates a more potent antiviral response than Toll-like receptor 4. <i>J Immunol</i> . 2003 Apr 1;170(7):3565-71.	

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	35	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C71	DREXLER <i>et al.</i> , Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells. Blood. 1989 Oct;74(5):1747-57.	
	C72	DZIOBEK <i>et al.</i> BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol. 2000 Dec 1;165(11):6037-46.	
	C73	EDWARDS <i>et al.</i> , Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. Eur J Immunol. 2003 Apr;33(4):827-33.	
	C74	ERIKS <i>et al.</i> , Histamine H2-receptor agonists. Synthesis, in vitro pharmacology, and qualitative structure-activity relationships of substituted 4- and 5-(2-aminoethyl)thiazoles. J Med Chem. 1992 Aug 21;35(17):3239-46.	
	C75	FECCI <i>et al.</i> , The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. J Neurooncol. 2003 Aug-Sep;64(1-2):161-76.	
	C76	FITZGERALD-BOCARSLY <i>et al.</i> , Virally-Responsive IFN- $\alpha$ Producing Cells in Human Blood and Tonsil Are CD11C/CD123+ Cells Identical to Precursors of Type Two Dendritic Cells (pDC2). J Interferon Cytokine Res. 1999;19(1):S117.	
	C77	FLO <i>et al.</i> , Involvement of toll-like receptor (TLR) 2 and TLR4 in cell activation by mannuronic acid polymers. J Biol Chem. 2002 Sep 20;277(38):35489-95. Epub 2002 Jun 27.	
	C78	FONTENAU <i>et al.</i> , Human Immunodeficiency Virus Type 1 Activates Plasmacytoid Dendritic Cells and Concomitantly Induces the Bystander Maturation of Myeloid Dendritic Cells. J Virol. 2003;78(10):5223-32.	
	C79	FRANKEL <i>et al.</i> , The Preparation of N-Disubstituted Formamides. Tetrahedron Lett. 1959;7:5-7.	
	C80	FRANTZ <i>et al.</i> , Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest. 1999 Aug;104(3):271-80.	

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	36	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C81	FU <i>et al.</i> , Regioselective Catalytic Hydrogenation of Polycyclic Aromatic Hydrocarbons under Mild conditions. J Org Chem. 1980;45:2979-803.	
	C82	FUCHSBERGER <i>et al.</i> , Priming Interferon-a 1 or Interferon-a 2 Enhances the Production of Both Subtypes Simultaneously. J Interferon and Cytokine Res. 1995;15:637-39.	
	C83	GALOSE, DAPSONE (diaminodiphenylsulphone DDS). Clinical Toxicology Review. 1999;21(9). 3 pages.	
	C84	GENDRON, Loxosceles ecluse envenomation. Am J Emerg Med. 1990 Jan;8(1):51-4.	
	C85	GENEVOIS-BORELLA <i>et al.</i> , Synthesis of 1-(3-R-Amino-4-Hydroxy Butyl)thymine Acyclonucleoside. Analogs as Potential Anti-AIDS Drugs. Tetrahedron Lett. 1990;31:4879-82.	
	C86	GIBSON <i>et al.</i> , Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J Interferon Cytokine Res. 1995 Jun;15(6):537-45.	
	C87	GIBSON <i>et al.</i> , Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol. 2002 Jul-Aug;218(1-2):74-86.	
	C88	GITELSON <i>et al.</i> , Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines. Clin Cancer Res. 2003 May;9(5):1656-65.	
	C89	GOMEZ <i>et al.</i> , Intradermal anti-loxosceles Fab fragments attenuate demonecrotic arachnidism. Acad Emerg Med. 1999;6:1195-202.	
	C90	GORDEN <i>et al.</i> , Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol. 2005 Feb 1;174(3):1259-68.	

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	37	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C91	GORDON, Pattern recognition receptors: doubling up for the innate immune response. Cell. 2002 Dec 27;111(7):927-30.	
	C92	GÜRSEL <i>et al.</i> , Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukoc Biol. 2002 May;71(5):813-20.	
	C93	GUNNING <i>et al.</i> , Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice. Cancer Res. 2002 Aug 1;62(15):4199-201.	
	C94	HART, Napthyridines Hydroxynaphthyridines, Journal of Chemical Society, 1956;Part III:212-4.	
	C95	HARTMANN <i>et al.</i> , Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol. 2003 Jun;33(6):1633-41.	
	C96	HAYASHI Toll-like receptors stimulate human neutrophil function. Blood. 2003 Oct 1;102(7):2660-9. Epub 2003 Jun 26.	
	C97	HAYES <i>et al.</i> , Regulation of Interferon Production by Human Monocytes: Requirements for Priming for Lipopolysaccharide-Induced Production. J Leukocyte Biol. 1991;50:176-81.	
	C98	HEIL <i>et al.</i> , Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004 Mar 5;303(5663):1526-9. Epub 2004 Feb 19.	
	C99	HEIL <i>et al.</i> , Synthetic immunostimulatory compounds activate immune cells via TLR7 and TLR8. 33th Annual Meeting of the Deutsche Gessellschaft Mr Immunologie, Marburg 2002. Abstract C.6.	
	C100	HEMMI <i>et al.</i> , Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002 Feb;3(2):196-200. Epub 2002 Jan 22.	

Examiner Signature	/Nillofar Rahmani/	Date Considered	08/24/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	38	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C101	HOBBS <i>et al.</i> , Comparison of hyperbaric oxygen and dapsone therapy for loxosceles envenomation. Acad Emerg Med. 1996 Aug;3(8):758-61.	
	C102	HOFFMAN <i>et al.</i> , Conformational requirements for histamine H2-receptor inhibitors: a structure-activity study of phenylene analogues related to cimetidine and tiotidine. J Med Chem. 1983 Feb;26(2):140-4.	
	C103	HOFMANOVÁ <i>et al.</i> , Lipoygenase inhibitors induce arrest of tumor cells in S-phase of the cell cycle. Neoplasma. 2002;49(6):362-7.	
	C104	HOLLADAY <i>et al.</i> , Structure-activity studies related to ABT-594, a potent nonopioid analgesic agent: effect of pyridine and azetidine ring substitutions on nicotinic acetylcholine receptor binding affinity and analgesic activity in mice. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2797-802.	
	C105	HORNG <i>et al.</i> , The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature. 2002 Nov 21;420(6913):329-33.	
	C106	HORNUNG <i>et al.</i> , Quantitative Expression of Toll-Like Receptor 1-10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides. Journal of Immunol. 2002;168:4531-37.	
	C107	HOUBEN-WEYL, Quinoline and Isoquinoline. Methoden der Organischen Chemie. 1980:271-79. German.	✓
	C108	HOUSTON <i>et al.</i> , Potential inhibitors of S-adenosylmethionine-dependent methyltransferases. 8. Molecular dissections of carbocyclic 3-deazaadenosine as inhibitors of S-adenosylhomocysteine hydrolase. J Med Chem. 1985 Apr;28(4):467-71.	
	C109	HUPPATZ, Systemic fungicides. The synthesis of certain pyrazole analogues of carboxin. Aust J Chem. 1983;36:135-47.	
	C110	IINO <i>et al.</i> , Treatment of Chronic Hepatitis C With High-Dose Interferon α-2b. Multicenter Study. Dig Dis Sci. 1993;38(4):612-18.	

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	39	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C111	ITO <i>et al.</i> , Interferon- $\alpha$ and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med. 2002 Jun 3;195(11):1507-12.	
	C112	IWASHITA <i>et al.</i> , Syntheses of Isoretronecanol and Lupinine. J Org Chem. 1982;47:230-33.	
	C113	JACOBS, The Synthesis of Acetylenes. In: Organic Reactions. New York: Wiley & Sons, Inc., 1949. Volume 5. 1-78.	
	C114	JAHNSEN <i>et al.</i> , Extensive recruitment of IL-3R $\alpha$ high dendritic-cell precursors to allergic nasal mucosa during allergen challenge. Immunology Lett. 1999;69(1):123. Abstract #32.2.	
	C115	JURK <i>et al.</i> Human TLR7 and TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol. 2002 Jun;3(6):499.	
	C116	JUWEID, Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma: From Clinical Trials to Clinical Practice. J Nuclear Med. 2002;43(11):1507-29.	
	C117	KATRITSKY <i>et al.</i> , Comprehensive Heterocyclic Chemistry: The Structure, Reactions, Synthesis and Uses of Heterocyclic Compounds. 1984;2:586-587.	
	C118	KEATING <i>et al.</i> , Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood. 1993 Jun 1;81(11):2878-84.	
	C119	KLAUSEN <i>et al.</i> , Two complementary methods of assessing periodontal bone level in rats. Scand J Dent Res. 1989 Dec;97(6):494-9.	
	C120	KLINMAN, Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 2004 Apr;4(4):249-58.	

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
-----------------------	--------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>		
				Application Number	10/595,103-Conf. #2609	
				Filing Date	February 14, 2006	
				First Named Inventor	Kyle J. Lindstrom	
				Art Unit	1625	
Examiner Name	N. Rahmani					
Sheet	40	of	57	Attorney Docket Number	C1271.70021US02	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C121	KLOEK <i>et al.</i> , An Improved Method for the Synthesis of Stabilized Primary Enamines and Imines. J Org Chem. 1978;43:1460-62.	
	C122	KLOETZEL, Reactions of nitroparaffins. I. Synthesis and reduction of some o -nitrokenes. J Am Chem Soc. 1947;69:2271-2275.	
	C123	KORNMAN, Host modulation as a therapeutic strategy in the treatment of periodontal disease. Clin Infect Dis. 1999 Mar;28(3):520-6.	
	C124	KOURAFALOS <i>et al.</i> , Synthesis of 7-aminopyrazolo[3,4-c]pyridine as a probe for the preparation of compounds of pharmacological interest. Heterocycles. 2002;57(12):2335-2343.	
	C125	KRAUSE <i>et al.</i> , Autoimmune aspects of cytokine and anticytokine therapies. Am J Med. 2003 Oct 1;115(5):390-7.	
	C126	KRENITSKY <i>et al.</i> , Imidazo[4,5-c]pyridines (3-deazapurines) and their nucleosides as immunosuppressive and anti-inflammatory agents. J Med Chem. 1986 Jan;29(1):138-43.	
	C127	KURT-JONES <i>et al.</i> , Role of toll-like receptor 2 (TLR2) in neutrophil activation: GM-CSF enhances TLR2 expression and TLR2-mediated interleukin 8 responses in neutrophils. Blood. 2002 Sep 1;100(5):1860-8.	
	C128	LALL <i>et al.</i> , Serine and threonine beta-lactones: a new class of hepatitis A virus 3C cysteine proteinase inhibitors. J Org Chem. 2002 Mar 8;67(5):1536-47.	
	C129	LEE <i>et al.</i> , p38 mitogen-activated protein kinase inhibitors – mechanisms and therapeutic potentials. Pharmacol Ther. 1999;82:389-97.	
	C130	LEE <i>et al.</i> , Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J Biol Chem. 2004 Apr 23;279(17):16971-9. Epub 2004 Feb 13.	

Examiner Signature	/Niloofar Rahmani/	Date Considered	08/24/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/



Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/595,103-Conf. #2609	
			Filing Date	February 14, 2006	
			First Named Inventor	Kyle J. Lindstrom	
			Art Unit	1625	
			Examiner Name	N. Rahmani	
Sheet	41	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C131	LEHNER <i>et al.</i> , The role of $\gamma\delta$ cells and $\beta$ -chemokines in mucosal protection against SIV infection. <i>Immunology Lett.</i> 1999;69:25-192. Abstract 2.1	
	C132	LEVY <i>et al.</i> , Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. <i>Blood</i> . 2006 Aug 15;108(4):1284-90. Epub 2006 Apr 25.	
	C133	LEYNADIER <i>et al.</i> , Allergic reactions to North African scorpion venom evaluated by skin test and specific IgE. <i>J Allergy Clin Immunol.</i> 1997 Jun;99(6 Pt 1):851-3. 4 pages.	
	C134	LI <i>et al.</i> , An improved protocol for the preparation of 3-pyridyl- and some arylboronic acids. <i>J Org Chem.</i> 2002 Jul 26;67(15):5394-7.	
	C135	LI <i>et al.</i> , Solubility behavior of imiquimod in alkanolic acids. <i>Pharmaceutical Research</i> . 1997 American Association of Pharmaceutical Scientists Annual Meeting. Poster Presentation, Boston, MA, Nov. 2-6, 1997;S475:Abstract 3029.	
	C136	LI <i>et al.</i> , Synthesis, CoMFA analysis, and receptor docking of 3,5-diacetyl-2, 4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. <i>J Med Chem.</i> 1999 Feb 25;42(4):706-21.	
	C137	LITT <i>et al.</i> , Mucosal delivery of vaccine antigens displayed on the surface of <i>Lactococcus lactis</i> . <i>Immunology Lett.</i> 1999;69(1):61. Abstract #11.26.	
	C138	LIU <i>et al.</i> , Synthesis of halogen-substituted 3-deazaadenosine and 3-deazaguanosine analogues as potential antitumor/antiviral agents. <i>Nucleosides Nucleotides Nucleic Acids</i> . 2001 Dec;20(12):1975-2000.	
	C139	LOESCHE <i>et al.</i> , Treatment paradigms in periodontal disease. <i>Compend Contin Educ Dent.</i> 1997 Mar;18(3):221-6, 228-30, 232 passim; quiz 234. Review.	
	C140	LUGER <i>et al.</i> , Evidence for an epidermal cytokine network. <i>J Invest Dermatol.</i> 1990 Dec;95(6 Suppl):100S-104S.	

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	42	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C141	LUSKIN <i>et al.</i> , Olefinic Derivatives of 2,4-Diamino-s-triazines. J Org Chem. 1958;23:1032-37.	
	C142	MACCHIA <i>et al.</i> , Synthesis and antiviral properties of 9-[(2-methyleneaminoxyethoxy)methyl]guanine derivatives as novel Acyclovir analogues. Farmaco. 2000 Feb;55(2):104-8.	
	C143	MAJESKI <i>et al.</i> , Action of venom from the brown recluse spider ( <i>Loxosceles ecluse</i> ) on human neutrophils. Toxicol. 1977;15(5):423-7.	
	C144	MAKARENKOVA <i>et al.</i> , Identification of delta- and mu- type opioid receptors on human and murine dendritic cells. J Neuroimmunol. 2001;117:68-77.	
	C145	MASIH, Progress on novel immunomodulatory agents for HIV-1 infection and other infectious diseases. Expert Opin Ther Patents. 2003;13(6):867-82.	
	C146	MASIUKIEWICZ <i>et al.</i> , Scalable Syntheses of N <sup>α</sup> -Benzyloxycarbonyl-L-Ornithine and of N <sup>α</sup> -(9-Fluorenylmethoxy)Carbonyl-L-Ornithine. Org Prep Proced Int. 2002;34:531-37.	
	C147	MATAKA <i>et al.</i> , Condensation reaction of 3,4-Dibenzoyl-1-methyl-2,5-diphenylpyrrole and -1-phenylpyrazole with methylamine derivatives affording pyrrolo [3,4-c] pyridine and 2H-pyrazolo[3,4-c]- and [4,3-c]pyridines. Journal of Heterocyclic Chemistry. 1981;18(6):1073-5.	
	C148	MATHUR <i>et al.</i> , Cell-mediated immune system regulation in periodontal diseases. Crit Rev Oral Biol Med. 1997;8(1):76-89.	
	C149	MAYNOR <i>et al.</i> , Brown recluse spider envenomation: a prospective trial of hyperbaric oxygen therapy. Acad Emerg Med. 1997 Mar;4(3):184-92.	
	C150	MBOW <i>et al.</i> , Small molecule and biologic modulators of the immune response to hepatitis C virus. Mini Rev Med Chem. 2006 May;6(5):527-31.	

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	43	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C151	MCCARTHY <i>et al.</i> , Opioids, opioid receptors, and the immune response. Drug & Alcohol Dependence. 2001;62:111-23.	
	C152	MCKENNON <i>et al.</i> , A Convenient Reduction of Amino Acids and Their Derivatives. J Org Chem. 1993;58:3568-71.	
	C153	MCLAUGHLIN <i>et al.</i> , Opioid growth factor (OGF) inhibits the progression of human squamous cell carcinoma of the head and neck transplanted into nude mice. Cancer Lett. 2003;199:209-17.	
	C154	MEDZHITOV, Toll-Like Receptors and Innate Immunity. Nature Rev Immunol. 2001;1:135-45.	
	C155	MEE <i>et al.</i> , Stille coupling made easier - the synergic effect of copper(I) salts and the fluoride ion. Angew Chem. 2004;116:1152-56.	
	C156	MERIGIAN <i>et al.</i> , Envenomation From the Brown Recluse Spider: Review of Mechanism and Treatment Options. Am J Ther. 1996 Oct;3(10):724-734.	
	C157	MILLER <i>et al.</i> , Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol. 1999 Jan;21(1):1-14.	
	C158	MINAKAWA <i>et al.</i> , Nucleosides and Nucleotides. 184. Synthesis and Conformational Investigation of Anti-Fixed 3-Deaza-3-halopurine Ribonucleosides. J Org Chem. 1999;64:7158-72.	
	C159	MOEBIUS <i>et al.</i> , The mysteries of sigma receptors: new family members reveal a role in cholesterol synthesis. Trends Pharmacol Sci. 1997 Mar;18(3):67-70.	
	C160	MOLDOVEANU <i>et al.</i> , Poly-L-lysine as a potential mucosal adjuvant. Immunology Lett. 1999;69(1):62. Abstract #11.28.	

Examiner Signature	/Nilofar Rahmani/	Date Considered	08/24/2010
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	44	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C161	MOLLIK <i>et al.</i> , MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. Cancer Immun. 2003 Mar 17;3:3. 17 pages.	
	C162	MOODY <i>et al.</i> , Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth. Exp Lung Res. 1998 Jul-Aug;24(4):617-28.	
	C163	MORACZEWSKI <i>et al.</i> , Using Hydrogen Bonding to Control Carbamate C-N Rotamer Equilibria. Org Chem. 1998 Oct 16;63(21):7258-7262.	
	C164	MOSBECH <i>et al.</i> , [Allergy to insect stings] Ugeskr Laeger. 1991 Oct 28;153(44):3067-71. Danish.	✓
	C165	MUCHE <i>et al.</i> , Imiquimod treatment of cutaneous T cell lymphoma. Journal of Investigative Dermatology. 2003 July;121(1):0975. Joint Meeting of the European Society for Dermatology; Miami Beach, Florida, USA. April 30-May 04, 2003. Abstract 0975.	
	C166	MULLER <i>et al.</i> , An improved one-pot procedure for the synthesis of alkynes from aldehydes. Synlett. 1996;6:521-522.	
	C167	MUTSCHLER <i>et al.</i> , 9.2 Anti-infectives. In: Drug Actions: Basic Principles and Therapeutic Aspects. 1995:515-23.	
	C168	MUZIO <i>et al.</i> , Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol. 2000 Jun 1;164(11):5998-6004.	
	C169	NAGARAJAN <i>et al.</i> , Condensed heterotricycles: synthesis of pyrazolo[3,4-c]quinoline derivatives. Indian Journal of Chemistry. 1992;31B:316-321.	
	C170	NAGASE <i>et al.</i> , Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. J Immunol. 2003 Oct 15;171(8):3977-82.	

Examiner Signature	/Nilofar Rahmani/	Date Considered	08/24/2010
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	45	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C171	NANJAPPAN <i>et al.</i> , An efficient synthesis of some 6-substituted 4,8-diaza-3,3,9,9-tetramethylundeca-2,10-dione dioximes (propylene amine oximes, PnAOs): Ligands for 99mTc complexes used in structure distribution relationship (SDR) studies. Tetrahedron. 1994;50(29):8617-32.	
	C172	OHANA <i>et al.</i> , Differential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptor. Journal of Cellular Physiology. 2001 Jan;186(1):19-23. Review.	
	C173	O'MAHONY <i>et al.</i> , New patient-applied therapy for anogenital warts is rated favourably by patients. Intl J STD & AIDS. 2001;12:565-70.	
	C174	OSOL <i>et al.</i> , Chapter 27: Structure-Activity Relationship and Drug Design. In: Remington's Pharmaceutical Sciences. 16th Ed. Mach Publishing. 1980:420-35.	
	C175	OTTONELLO <i>et al.</i> , Sulphonamides as anti-inflammatory agents: old drugs for new therapeutic strategies in neutrophilic inflammation? Clin Sci (Lond). 1995 Mar;88(3):331-6.	
	C176	OZINSKY <i>et al.</i> , The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. Proc. Nat. Acad. Sci. 2000; 97(25):13766-71.	
	C177	PAGE <i>et al.</i> , Advances in the pathogenesis of periodontitis: summary of developments, clinical implications and future directions. Periodontol 2000. 1997 Jun;14:216-48.	
	C178	PARK <i>et al.</i> , Immunotherapy Cancer Treatment. Reprinted from Supportive Cancer Care, Rosenbaum <i>et al.</i> 2001. Available at <a href="http://www.cancersupportivecare.com/immunotherapy.html">http://www.cancersupportivecare.com/immunotherapy.html</a> . Last accessed July 13, 2010. 3 pages.	
	C179	PARK <i>et al.</i> , Sodium Dithionite Reduction of Nitroarenes Using Viologen as an Electron Phase-Transfer Catalyst. Tetrahedron Lett. 1993;34(46):7445-46.	
	C180	PATEL <i>et al.</i> , The necrotic venom of the brown recluse spider induces dysregulated endothelial cell-dependent neutrophil activation. Differential induction of GM-CSF, IL-8, and E-selectin expression. J Clin Invest. 1994 Aug;94(2):631-42.	

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	46	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C181	PATRICK <i>et al.</i> , Paragraph 10.3: Drug optimization: strategies in drug design. In: An Introduction to Medicinal Chemistry. Oxford: Oxford University Press. January 2005. 200-218.	
	C182	PAVLETIC <i>et al.</i> , Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant. 2000 Apr;25(7):717-22.	
	C183	PAWLAS <i>et al.</i> , Novel anionic annelation tactics for construction of fused heteroaromatic frameworks. 1. Synthesis of 4-substituted pyrazolo[3,4-c]quinolines, 9-substituted pyrazolo[3,4-c]quinolines, and 1,4-dihydrochromeno[4,3-c]pyrazoles. Org Chem. 2001 Jun 15;66(12):4214-9.	
	C184	PAYVANDI <i>et al.</i> , Exogenous and Endogenous IL-10 Regulate IFN- $\alpha$ Production by Peripheral Blood Mononuclear Cells in Response to Viral Stimulation. J Immunol. 1998;160:5861-68.	
	C185	PESCHKE <i>et al.</i> , Synthesis and in vitro characterization of new growth hormone secretagogues derived from ipamorelin with dipeptidomimetic N-terminals. Eur J Med Chem. 1999;34:363-380.	
	C186	PETERSON <i>et al.</i> , The opioid-cytokine connection. J Neuroimmunol. 1998;83:63-69.	
	C187	PHILLIPS <i>et al.</i> , Therapy of brown spider envenomation: a controlled trial of hyperbaric oxygen, dapsone, and cyproheptadine. Ann Emerg Med. 1995 Mar;25(3):363-8.	
	C188	PICKERSGILL <i>et al.</i> , Preparation of functionalized, conformationally constrained DTPA analogues from L- or D-serine and trans-4-hydroxy-L-proline. Hydroxymethyl substituents on the central acetic acid and on the backbone. J Org Chem. 2000 Jun 30;65(13):4048-57.	
	C189	POLJAKOVIC <i>et al.</i> , iNOS and COX-2 immunoreactivity in the mice bladder and kidney after bacterial instillation. Immunology Lett. 1999;69(1):122. Abstract #31.5.	
	C190	POWELL <i>et al.</i> , Compendium of excipients for parenteral formulations. PDA J Pharm Sci Technol. 1998 Sep-Oct;52(5):238-311.	

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	47	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C191	PRELOG <i>et al.</i> , Cycloalkeno-pyridine. <i>Helv Chem Acta</i> . 1945;28:1684-93. German.	
	C192	REES <i>et al.</i> , Brown recluse spider bites. A comparison of early surgical excision versus dapsone and delayed surgical excision. <i>Ann Surg</i> . 1985 Nov;202(5):659-63.	
	C193	REGAN <i>et al.</i> , Activation of p38 MAPK by feline infectious peritonitis virus regulates pro-inflammatory cytokine production in primary blood-derived feline mononuclear cells. <i>Virology</i> . 2009 Feb 5;384(1):135-43. Epub 2008 Dec 5.	
	C194	RHODES, Discovery of immunopotentiatory drugs: current and future strategies. <i>Clin Exp Immunol</i> . 2002 Dec;130(3):363-9.	
	C195	RIBERA <i>et al.</i> , "Spontaneous" complete remissions in chronic lymphocytic leukemia: report of three cases and review of the literature. <i>Blood Cells</i> . 1987;12(2):471-83.	
	C196	RITTER <i>et al.</i> , A new reaction of nitriles; amides from alkenes and mononitriles. <i>J Am Chem Soc</i> . 1948 Dec;70(12):4045-8.	
	C197	ROCCA <i>et al.</i> , Carbolines. Part VII. Ansindines, Convenient tools to synthesize efficient-β-carbolines. <i>J Heterocyclic Chem</i> . 1995;32:1171-1175.	
	C198	ROCCA <i>et al.</i> , Connection between metalation and cross-coupling strategies. A new convergent route to azacarbazoles. 1993;49(1):49-64.	
	C199	ROLLINS <i>et al.</i> , Chemokines. <i>Blood</i> . 1997 Aug 1;90(3):909-28. Review.	
	C200	ROSENBERG <i>et al.</i> , Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. <i>JAMA</i> . 1994 Mar 23-30;271(12):907-13.	

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete If Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	48	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C201	ROTHEL <i>et al.</i> , The use of recombinant ovine IL-1beta and TNF-alpha as natural adjuvants and their physiological effects in vivo. Immunol Cell Biol. 1998 Apr;76(2):167-72.	
	C202	ROY <i>et al.</i> , QSAR of adenosine receptor antagonists II: exploring physicochemical requirements for selective binding of 2-arylpyrazolo[3,4-c] quinoline derivatives with adenosine A1 and A3 receptor subtypes. QSAR & Comb Sci. 2003;22:614-621.	
	C203	ROYALS <i>et al.</i> , Studies in mixed ester condensations. IV. Acylations with methyl dimethoxyacetate. J Am Chem Soc. 1956;78:4161-4164.	
	C204	ROZMAN <i>et al.</i> , Chronic lymphocytic leukemia. N Engl J Med. 1995 Oct 19;333(16):1052-7.	
	C205	SAKTHIVEL <i>et al.</i> Direct SnAr amination of fluorinated imizazo[4,5-c]pyridine nucleosides: efficient synthesis of 3-fluoro-3-3-deazaadenosine analogs. Tetrahedron Letters. 2005 May;46(22):3883-3887.	
	C206	SALAUN <i>et al.</i> , TLR3 Can Directly Trigger Apoptosis in Human Cancer Cells. J of Immunology. 2006;176:4894-901.	
	C207	SALEMINK, Uber 2-Propyl-1- Und 2-Propyl-Desaza-Adenin. Recueil. 1961;80:545-56. German.	
	C208	SAMBHI <i>et al.</i> , Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo. Proc Natl Acad Sci U S A. 1991 May 1;88(9):4025-9.	
	C209	SAMS <i>et al.</i> , Necrotic arachnidism. J Am Acad Dermatol. 2001 Apr;44(4):561-73; quiz 573-6.	
	C210	SAUDER <i>et al.</i> , Randomized, Single-Blind, Placebo-Controlled Study of Topical Application of the Immune Response Modulator Resiquimod in Healthy Adults. Antimicrobial Agents Chemo. 2003;47(12):3846-52.	

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	49	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C211	SCHEERLINCK, Genetic adjuvants for DNA vaccines. Vaccine. 2001 Mar 21;19(17-19):2647-56.	
	C212	SCHEUER <i>et al.</i> , Application of the Ritter reaction to mesityl oxide and chalcone. J Am Chem Soc. 1957;22:674-676.	
	C213	SCHOFIELD <i>et al.</i> , Reply. Low-Dose Interferon-alpha in Chronic Myeloid Leukemia. Ann Internal Med. 1995;122(9):728-29. 1 page.	
	C214	SCHWANDNER <i>et al.</i> , Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem. 1999 Jun 18;274(25):17406-9.	
	C215	SEEMAN <i>et al.</i> , Steric and Conformational Effects in Nicotine Chemistry. J Org Chem. 1981;46:3040-48.	
	C216	SERRAT <i>et al.</i> , A highly efficient and straightforward stereoselective synthesis of novel chiral $\alpha$ -acetylenic ketones. Tetrahedron: Asymmetry. 1999;10:3417-30.	
	C217	SEVERA <i>et al.</i> , Sensitization to TLR7 agonist in IFN-beta-preactivated dendritic cells. J Immunol. 2007 May 15;178(10):6208-16.	
	C218	SEYMOUR <i>et al.</i> , Cellular immunity and hypersensitivity as components of periodontal destruction. Oral Dis. 1996 Mar;2(1):96-101. Review.	
	C219	SHELBOURNE <i>et al.</i> , Quantitation of Bacteroids forsythus in subgingival plaque comparison on immunoassay and quantitative polymerase chain reaction. J Microbiol Methods. 2000;39:97-107.	
	C220	SIDKY <i>et al.</i> , Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res. 1992 Jul 1;52(13):3528-33.	

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
-----------------------	--------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	50	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C221	SIEGAL <i>et al.</i> , The nature of the principal type 1 interferon-producing cells in human blood. Science. 1999 Jun 11;284(5421):1835-7.	
	C222	SLETZINGER <i>et al.</i> , The Synthesis of Isomethadone. J Am Chem Soc. 1952;74:5619-20.	
	C223	SMITH <i>et al.</i> , The role of polymorphonuclear leukocytes in the lesion caused by the venom of the brown spider, <i>Loxosceles ecluse</i> . Lab Invest. 1970 Jan;22(1):90-3.	
	C224	SOFINA <i>et al.</i> , Experimental evaluation of antitumor drugs in the USA and USSR and clinical correlations. NCI Monograph 55. NIH Publication No. 80-1933. 1980:76-8.	
	C225	SONOGASHIRA <i>et al.</i> , A convenient synthesis of acetylenes: catalytic substitutions of acetylenic hydrogen with bromoalkenes, Iodoarenes, and bromopyridines. Tetrahedron Letts. 1975;50:4467-4470.	
	C226	SORIA <i>et al.</i> , Effect of food on the pharmacokinetics and bioavailability of oral imiquimod relative to a subcutaneous dose. Int J Clin Pharmacol Ther. 2000 Oct;38(10):476-81.	
	C227	SPANER <i>et al.</i> , A phase I/II trial of TLR -7 agonist immunotherapy in chronic lymphocytic leukemia. Leukemia. 2010; 24:222-26.	
	C228	SPANER <i>et al.</i> , Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia. 2006 Feb;20(2):286-95.	
	C229	SPANER <i>et al.</i> , Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia. 2007 Jan;21(1):53-60. Epub 2006 Oct 26.	
	C230	SPIVEY <i>et al.</i> , Configurationally stable biaryl analogues of 4-(dimethylamino)pyridine: A novel class of chiral nucleophilic catalysts. J Org Chem. 1999;64:9430-9443.	

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
-----------------------	--------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	51	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C231	SPRUANCE <i>et al.</i> , Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J Infect Dis. 2001 Jul 15;184(2):196-200. Epub 2001 Jun 8.	
	C232	STACK, Images in clinical medicine. Latrodectus mactans. N Engl J Med. 1997 Jun 5;336(23):1649.	
	C233	STANLEY, Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol. 2002 Oct;27(7):571-7. Review.	
	C234	STASHENKO <i>et al.</i> , Periapical inflammatory responses and their modulation. Crit Rev Oral Biol Med. 1998;9(4):498-521.	
	C235	STEELE <i>et al.</i> , Lipoxigenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev. 1999 May;8(5):467-83.	
	C236	STEELE <i>et al.</i> , Potential use of lipoxigenase inhibitors for cancer chemoprevention. Expert Opin Investig Drugs. 2000 Sep;9(9):2121-38.	
	C237	STEINMANN <i>et al.</i> , Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol. 2000 Sep;43(3):555-6.	
	C238	STEWART <i>et al.</i> , Synthesis of a Carba-analog of S-Acetyl Coenzyme A, Acetyl-dethio Coenzyme A; an Effective Inhibitor of Citrate Synthase. Liebigs Ann Chem. 1978:57-65.	
	C239	STILLINGS <i>et al.</i> , Substituted 1,3,4-thiadiazoles with anticonvulsant activity. 2. Aminoalkyl derivatives. J Med Chem. 1986 Nov;29(11):2280-4.	
	C240	STRANDTMANN <i>et al.</i> , Reaction of cyclic $\beta$ -diketones with 3,4-dihydroisoquinolines and related compounds. Preparation and anticancer activity of 2-substituted 1,3-cyclohexanediones. J Med Chem. 1967 Nov;10(6):1063-5.	

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	52	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C241	STRINGFELLOW, Induction of interferon with low molecular weight compounds: fluorenone esters, ethers (tilorone), and pyrimidinones. <i>Methods Enzymol.</i> 1981;78(Pt A):262-84.	
	C242	STRÖHER <i>et al.</i> , Progress towards the treatment of Ebola haemorrhagic fever. <i>Expert Opin Investig Drugs.</i> 2006 Dec;15(12):1523-35.	
	C243	SUGISAKA <i>et al.</i> , The Physicochemical properties of imiquimod, the first imidazoquinoline immune response modifier. <i>Pharmaceutical Research.</i> 1997 American Association of Pharmaceutical Scientists Annual Meeting. Poster Presentation, Boston, MA, Nov. 2-6, 1997;S475:Abstract 3030.	
	C244	SURREY <i>et al.</i> , The Synthesis of Some 3-Nitro- and 3-Amino-4-dialkylaminoalkylaminoquinoline Derivatives. <i>J Am Chem Soc.</i> 1951;73:2413-16.	
	C245	TAKEICHI <i>et al.</i> , Cytokine profiles of T-lymphocytes from gingival tissues with pathological pocketing. <i>J Dent Res.</i> 2000 Aug;79(8):1548-55.	
	C246	TAKESHITA <i>et al.</i> , Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. <i>Semin Immunol.</i> 2004 Feb;16(1):17-22.	
	C247	TAKEUCHI <i>et al.</i> , Discrimination of bacterial lipoproteins by Toll-like receptor 6. <i>Int Immunol.</i> 2001 Jul;13(7):933-40.	
	C248	TEMPLE <i>et al.</i> , Potential anticancer agents: 5-(N-substituted-aminocarbonyl)- and 5-(N-substituted-aminothiocarbonyl)-5,6,7,8-tetrahydrofolic acids. <i>J Med Chem.</i> 1988 Mar;31(3):697-700.	
	C249	THESING <i>et al.</i> , [Darstellung und Eigenschaften des $\Delta^1$ -Pyrrolin-N-oxyds.]. <i>Chem Ber.</i> 1959;92:1748-55. German.	
	C250	THIRUVIKRAMAN <i>et al.</i> , Synthesis and reactions of pyrazolo-[3,4-c]quinoline derivatives. <i>Indian Journal of Chemistry.</i> 1987;26B:695-696.	

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	53	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C251	TOMAI <i>et al.</i> , Imiquimod: in vivo and in vitro characteristics and toxicology. In: Cutaneous Infection and Therapy. Aly <i>et al.</i> , eds. Marcel Dekkar, Inc., New York. 1997:406-15.	
	C252	TOMIC <i>et al.</i> , Sensitization of IL-2 Signaling through TLR-7 Enhances B Lymphoma Cell Immunogenicity. J Immunol. 2006;176:3830-39.	
	C253	TOMIOKA <i>et al.</i> , Asymmetric Alkylation of $\alpha$ -Alkyl $\beta$ -Keto Esters. J Am Chem Soc. 1984;106:2718-19.	
	C254	TOTTERMAN <i>et al.</i> , Phorbol ester-induced differentiation of chronic lymphocytic leukaemia cells. Nature. 1980 Nov 13;288(5787):176-8.	
	C255	TRACY <i>et al.</i> , Studies in the Pyridine Series. II. Synthesis of 2-Methyl-3-( $\beta$ -Hydroxyethyl)pyridine and of the Pyridine Analog of Thiamine (Vitamin B2). J Org Chem. 1941;6:54-62.	
	C256	UNO <i>et al.</i> , TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. Blood. 2003 May 1;101(9):3658-67. Epub 2002 Dec 27.	
	C257	UROSEVIC <i>et al.</i> , Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha? Clin Cancer Res. 2004 Aug 1;10(15):4959-70.	
	C258	VAN DE KERHOF, New Immunomodulatory Drugs. In: Skin and Environment: Perception and Protection. Ring <i>et al.</i> , eds., 10th EADV Congress, October 10-14, Munich, Germany. 2001:1:343-38.	
	C259	VASILAKOS <i>et al.</i> , Adjuvant Activities of Immune Response Modifier R-848: Comparison with CoG ODN. Cell Immunol. 2000;204:64-74.	
	C260	VIEWEG <i>et al.</i> , Tumor vaccines: from gene therapy to dendritic cells-the emerging frontier. Urol Clin North Am. 2003 Aug;30(3):633-43.	

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	54	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C261	VILCEK, The cytokines: An overview. In: The Cytokine Handbook, Fourth Ed. M. Lotze and A.W. Thompson (eds.), 2003;1:3-14.	
	C262	VOLHARDT, 18-5. Amides: The Least-Reactive Carboxylic Acid Derivatives. Organic Chemistry. 1987:813.	
	C263	VOLLMER <i>et al.</i> , Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):165-75.	
	C264	WAGNER <i>et al.</i> , Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463. Cytokine. 1997 Nov;9(11):837-45.	
	C265	WAGNER <i>et al.</i> , Modulation of TH1 and TH2 Cytokine Production with the Immune Response Modifiers, R-848 and Imiquimod. Cellular Immunology. 1999;191:10-19.	
	C266	WANG, Structure and Chemistry of 4-Hydroxy-6-methyl-2-pyridone. J Heterocyclic Chem. 1970;7:389-92.	
	C267	WARREN <i>et al.</i> , Macrophage Growth Factor CSF-1 Stimulates Human Monocyte Production of Interferon, Tumor Necrosis Factor, and Colony Stimulating Activity. J Immunol. 1986;137(7):2281-85.	
	C268	WASSERMAN <i>et al.</i> , Loxoscelism and necrotic arachnidism. J Toxicol Clin Toxicol. 1983-1984;21(4-5):451-72.	
	C269	WEDLOCK <i>et al.</i> , Physiological effects and adjuvanticity of recombinant brushtail possum TNF-alpha. Immunol Cell Biol. 1999 Feb;77(1):28-33.	
	C270	WELLS, Additivity of Mutational Effects in Proteins. Biochemistry. 1990;29(37):8509-17.	

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	55	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C271	WERMUTH, Molecular Variations Based on Isosteric Replacements. Practice of Medicinal Chemistry. 1996:203-37.	
	C272	WEXLER <i>et al.</i> , Accurate identification of experimental pulmonary metastases. J Natl Cancer Inst. 1966 Apr;36(4):641-5.	
	C273	WIBAUT <i>et al.</i> , Syntheses of 3,4-Dimethylpyridine, 2,3-Dimethylpyridine and 2-Methyl-3-Ethylpyridine. Rec Trav Chim. 1944;63:231-38.	
	C274	WIERDA <i>et al.</i> , CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood. 2000 Nov 1;96(9):2917-24.	
	C275	WIESELER-FRANK <i>et al.</i> , Central proinflammatory cytokines and pain enhancement. Neurosignals. 2005;14(4):166-74.	
	C276	WILLIAMS <i>et al.</i> , Grignard Reactions to Chiral Oxazolidine Aldehydes. Tetrahedron. 1996;52:11673-94.	
	C277	WILSON <i>et al.</i> , Spiders and spider bites. Dermatol Clin. 1990 Apr;8(2):277-86.	
	C278	WRIGHT <i>et al.</i> , Clinical presentation and outcome of brown recluse spider bite. Ann Emerg Med. 1997 Jul;30(1):28-32.	
	C279	WU <i>et al.</i> , Murine B16 melanoma vaccination-induced tumor immunity: identification of specific immune cells and functions involved. J Interferon Cytokine Res. 2001 Dec;21(12):1117-27.	
	C280	YAMAMOTO <i>et al.</i> , Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature. 2002 Nov 21;420(6913):324-9.	

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
-----------------------	--------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
Examiner Name	N. Rahmani				
Attorney Docket Number	C1271.70021US02				
Sheet	56	of	57		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C281	YEUNG-YUE <i>et al.</i> , The management of herpes simplex virus infections. Curr Opin Infect Dis. 2002 Apr;15(2):115-22.	
	C282	YUTILOV <i>et al.</i> , Synthesis and some reactions of 4-nitroimidazo[4-5-c]pyridin-2-ones. CAPLUS English Abstract DN 91:175261. VINITI.1978:1193-78. Abstract Only.	
	C283	ZAGON <i>et al.</i> , Immunoelectron microscopic localization of the opioid growth factor receptor (OGFr) and OGF in the cornea. Brain Res. 2003;967:37-47.	
	C284	ZAGON <i>et al.</i> , Opioids and the apoptotic pathway in human cancer cells. Neuropeptides. 2003;37:79-88.	
	C285	ZAGON <i>et al.</i> , The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev. 2002 Feb;38(3):351-76. Review.	
	C286	ZAGON <i>et al.</i> , The expression and function of the OGF-OGFr axis - a tonically active negative regulator of growth - in COS cells. Neuropeptides. 2003 Oct;37(5):290-7.	
	C287	ZAMBON, Periodontal diseases: microbial factors. Ann Periodontol. 1996 Nov;1(1):879-925.	
	C288	ZARUBIN <i>et al.</i> , Theoretical Study of Antagonists and Inhibitors of Mammalian Adenosine Deaminase: I. Adenosine and Its Aza- and Deazaanalogues. Russ J Bioorg Chem. 2002;28(4):284-92.	
	C289	ZHANG <i>et al.</i> , Structural features of azidopyridinyl neonicotinoid probes conferring high affinity and selectivity for mammalian alpha4beta2 and Drosophila nicotinic receptors. J Med Chem. 2002 Jun 20;45(13):2832-40.	
	C290	ZHU <i>et al.</i> , Inhibition of murine dendritic cell activation by synthetic phosphorothioate oligodeoxynucleotides. J Leukoc Biol. 2002 Dec;72(6):1154-63.	

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/595,103-Conf. #2609
				Filing Date	February 14, 2006
				First Named Inventor	Kyle J. Lindstrom
				Art Unit	1625
				Examiner Name	N. Rahmani
Sheet	57	of	57	Attorney Docket Number	C1271.70021US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C291	ZHU <i>et al.</i> , Inhibition of murine macrophage nitric oxide production by synthetic oligonucleotides. J Leukoc Biol. 2002 Apr;71(4):686-94.	
	C292	ZIEGLER-HEITBROCK <i>et al.</i> , Favorable response of early stage B CLL patients to treatment with IFN-alpha 2. Blood. 1989 May 1;73(6):1426-30.	
	C293	ZYRYANOV <i>et al.</i> , Heterocyclization of 1-(2'-Carbethoxyphenyl)-5-Methyltetrazole. Chemistry of Heterocyclic Compounds. English Edition. 1981;16(12):1286-88.	

Examiner Signature	/Niloofer Rahmani/	Date Considered	08/24/2010
-----------------------	--------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/